乙型肝炎表面抗原清除后肝细胞癌的长期发病率
本研究基于香港全港数据库,纳入2000至2022年间HBsAg清除的13379例慢性乙型肝炎患者,比较其肝细胞癌年发病率与一般人群。结果显示,年轻且无肝硬化的患者HCC风险极低,尤其是40岁以下男性和50岁以下女性无肝硬化者,可能无需常规监测。
要点
- HBsAg清除后总体HCC年发病率为0.43%(<50岁肝硬化)和0.62%(≥50岁肝硬化)。
- 无肝硬化且50岁前清除HBsAg者年发病率0.03%,与一般人群相当。
- 无肝硬化、50岁前清除HBsAg的女性15年随访无HCC发生。
核心结论
- 年轻、无肝硬化且无其他风险因素的HBsAg清除者HCC风险极低,可能无需常规监测。
研究设计与样本
- 基于香港全港数据库的回顾性队列研究,纳入2000至2022年间HBsAg清除的13379例成人慢性乙型肝炎患者。
主要发现
- 中位随访5.6年(25th-75th百分位3.1-9.8年),274例(2.0%)发生HCC。
- 肝硬化患者中,<50岁和≥50岁清除HBsAg的年HCC发病率分别为0.43%(95%CI 0.22%-0.73%)和0.62%(95%CI 0.50%-0.76%)。
- 无肝硬化且<50岁清除HBsAg者年发病率为0.03%(95%CI 0.01%-0.06%),与一般人群的0.03%相当。
- 无肝硬化男性<40岁和40-49岁清除HBsAg的年发病率分别为0.02%(95%CI 0.002%-0.08%)和0.09%(95%CI 0.03%-0.19%)。
- 无肝硬化且<50岁清除HBsAg的1317例女性在15年随访期间无HCC发生;50-59岁女性年发病率为0.06%(95%CI 0.02%-0.13%)。
临床怎么用
- 对于年轻、无肝硬化且无其他风险因素的HBsAg清除者,尤其是40岁以下男性和50岁以下女性,可考虑不进行常规HCC监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) decreases after hepatitis B surface antigen (HBsAg) seroclearance. We examined HCC incidence in patients with chronic hepatitis B (CHB) who cleared HBsAg compared with the general population. METHODS: All adults with CHB who cleared HBsAg between 2000 and 2022 were identified using a territory-wide database in Hong Kong. Annual HCC incidences were estimated and compared with the general population. Age- and sex-specific population statistics were retrieved from the Hong Kong Cancer Registry and Census and Statistics Department. RESULTS: Of 13,379 patients with HBsAg seroclearance (mean age, 59.7 ± 13.7 years; 59.8% men, 14.6% cirrhosis), HCC developed in 274 (2.0%) at a median of 5.6 years (25th-75th percentile, 3.1-9.8 years). Annual HCC incidence was 0.43% (95% confidence interval [CI], 0.22%-0.73%) and 0.62% (95% CI, 0.50%-0.76%) among patients with cirrhosis aged <50 years and ≥50 years at HBsAg seroclearance, respectively. In patients without cirrhosis who cleared HBsAg before age 50, the annual HCC incidence was 0.03% (95% CI, 0.01%-0.06%), comparable to 0.03% in general population. Annual HCC incidence of male patients without cirrhosis aged <40 and 40 to 49 years at HBsAg was 0.02% (95% CI, 0.002%-0.08%) and 0.09% (95% CI, 0.03%-0.19%), respectively. No HCC cases occurred during 15 years/ of follow-up among 1317 female patients without cirrhosis aged <50 years at HBsAg loss; the annual HCC incidence was 0.06% (95% CI, 0.02%-0.13%) among those aged 50 to 59 years. CONCLUSIONS: Patients with CHB who clear HBsAg at younger ages, particularly men <40 years and women <50 years without cirrhosis or additional risk factors, have very low HCC risk and may not require routine surveillance.
引用
- El-Debeiky S, Lam TH, Lai MS, et al. Long-Term Incidence of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance. Gastroenterology. 2026. PMID: 42442512. doi:10.1053/j.gastro.2026.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。